https://pharminent.com/oncology/oncology-intelligence-digest-july-17-2026/ 2026-07-18T19:41:29Z Pharminent en Oncology Intelligence Digest • July 17, 2026 2026-07-18T19:41:27Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-july-17-2026/ 2026-07-17T21:46:49Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • July 17, 2026 2026-07-17T21:46:47Z Blog https://pharminent.com/fda-converts-novartis-fabhalta-to-full-approval-in-iga-nephropathy/ 2026-07-17T21:12:31Z Pharminent en FDA Converts Novartis' Fabhalta to Full Approval in IgA Nephropathy 2026-07-17T20:31:45Z Blog https://pharminent.com/novo-lands-european-oral-wegovy-approval-before-lilly-can-respond/ 2026-07-17T20:31:42Z Pharminent en Novo Lands European Oral Wegovy Approval Before Lilly Can Respond 2026-07-17T20:31:42Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-july-17-2026/ 2026-07-17T20:12:12Z Pharminent en GLP-1 Competitive Market Digest • Weekly • July 17, 2026 2026-07-17T20:12:10Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-16-2026/ 2026-07-17T16:05:27Z Pharminent en Rare Disease & Gene Therapy Digest • July 16, 2026 2026-07-17T16:05:25Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-17-2026/ 2026-07-17T15:53:16Z Pharminent en Strategic News Watch • July 17, 2026 2026-07-17T15:53:14Z Blog